StockData
MindWalk Holdings Corp. logo

MindWalk Holdings Corp. (HYFT) stock

HYFTNasdaqPharmaceutical PreparationsFiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 20-F on Jul 23, 2026Score 7/30
$0.94−0.05 (-5.27%)

Close on Nov 16, 2026Market cap $43.81MP/E –Yield –

MindWalk r&d expenses

Research and development expenses are spending on new products and technology.

MindWalk's R&D Expenses for the twelve months ending Jul 31, 2026 was C$5.30M, up 39.6% year over year. For fiscal 2026 it was C$4.93M, up 17.2% from the year before. The highest annual figure on record is C$14.10M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Apr 30, 2026C$4.93M+17.2%
FY2025Apr 30, 2025C$4.21M+12.6%
FY2024Apr 30, 2024C$3.74M-73.5%
FY2023Apr 30, 2023C$14.10M+84.0%
FY2022Apr 30, 2022C$7.66M+288.2%
FY2021Apr 30, 2021C$1.97M+342.6%
FY2020Apr 30, 2020C$446.00K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jul 31, 2026C$1.29M+22.5%
Q4 FY2026CQ1 2026Apr 30, 2026C$1.57M+90.4%
Q3 FY2026CQ4 2025Jan 31, 2026C$1.21M+32.8%
Q2 FY2026CQ3 2025Oct 31, 2025C$1.23M+21.8%
Q1 FY2026CQ2 2025Jul 31, 2025C$1.05M-29.6%
Q4 FY2025CQ1 2025Apr 30, 2025C$825.00K-13.7%
Q3 FY2025CQ4 2024Jan 31, 2025C$914.00K-8.7%
Q2 FY2025CQ3 2024Oct 31, 2024C$1.01M+20.5%
Q1 FY2025CQ2 2024Jul 31, 2024C$1.49M+57.2%
Q4 FY2024CQ1 2024Apr 30, 2024C$956.00K+4.8%
Q3 FY2024CQ4 2023Jan 31, 2024C$1.00M-36.0%
Q2 FY2024CQ3 2023Oct 31, 2023C$835.00K-83.3%
Q1 FY2024CQ2 2023Jul 31, 2023C$947.00K–
Q4 FY2023CQ1 2023Apr 30, 2023C$912.00K–
Q3 FY2023CQ4 2022Jan 31, 2023C$1.56M–
Q2 FY2023CQ3 2022Oct 31, 2022C$5.00M–

More MindWalk figures

See a number that looks wrong?